Hinova Pharmaceuticals Inc. (SHA:688302)

China flag China · Delayed Price · Currency is CNY
42.60
+1.98 (4.87%)
At close: Mar 6, 2026
9.77%
Market Cap 4.16B
Revenue (ttm) 20.67M
Net Income (ttm) -136.69M
Shares Out 99.02M
EPS (ttm) -1.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,462,695
Average Volume 1,047,706
Open 40.29
Previous Close 40.62
Day's Range 40.29 - 42.68
52-Week Range 31.10 - 71.98
Beta -0.08
RSI 36.08
Earnings Date Apr 25, 2026

About Hinova Pharmaceuticals

Hinova Pharmaceuticals Inc., a clinical-stage pharmaceutical company, engages in the development and production of therapeutics for cancers and metabolic syndromes. It develops drugs based on proteolysis targeting chimera and deuteration technology. The company’s products pipeline includes HC-1119, a product in phase III clinical trials with castration resistant prostate cancer indications; HP501, a product in phase II clinical trials for the treatment of hyperuricemia and gout; HP558, a product in phase II clinical trials to treat various late... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 174
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688302
Full Company Profile

Financial Performance

In 2025, Hinova Pharmaceuticals's revenue was 20.67 million, an increase of 5535.71% compared to the previous year's 366,836. Losses were -136.69 million, -31.48% less than in 2024.

Financial Statements

News

There is no news available yet.